NEJM Journal Club   

Questions discussed in this category



Are there any circumstances where use of T-DXd would supercede the use of CDK4/6 inhibitors or other non-chemotherapeutic options?

Is there evidence that T-DXd crosses the blood-brain barrier?

Prior studies have shown that there can be significant variation between grading pathologists as to which samples are defined as HER2 IHC +1 versus HE...

What is the cost and accessibility of CYP2C19 gene testing? Does the limited availability of rapid genotyping techniques limit the clinical applicabil...

How do you plan to incorporate the results of the CHANCE-2 trial (Wang et al., PMID 34708996) in your own practice?

Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...

The FDA recently approved trastuzumab deruxtecan (T-DXd) in the second line setting. Given the results of DESTINY-Breast03, what is now the role of TD...

Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is cons...

Given OlympiA trial with olaparib benefit for gBRCA+ patients?What are barriers that you foresee? In your practice who performs mutation testing and w...

For example, would it be appropriate to consider JAK inhibitor therapy as preferable to TNF-alpha inhibitor in patients with heart failure with reduce...

Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?    

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...

Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line? How does prior Her2-directed and/or taxane therapy...

Does this raise concerns about the efficacy of adjuvant immune checkpoint inhibition? Are any preliminary results from AMBASSADOR (adjuvant pembrolizu...

Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts? Are ther...

Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or sta...

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...

Do you think adjuvant nivolumab should be the new standard of care based on current CM274 DFS data? If OS turns out to be no different, will you still...

How does prior chemotherapy, site of disease, and pathological staging inform your decision? How about molecular markers (PD-L1, ctDNA)?

Is a 3 month delay too long in someone who had postoperative complications?

NCCN recommends perioperative FLOT or FOLFOX vs. neoadjuvant chemoRT with Carboplatin/Paclitaxel or FOLFOX.Does CM-577 and the approval of nivolumab p...

Many of the patients on ASCENT trial were heavily pre-treated and require growth factors. With the day 1,8 treatment cycle, is there a way to minimize...

Are there other treatment variations by clinical subsets (eg tumor location, histology, stage II vs III, other biomarkers) seen in CM577 or other data...

CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.  

How are you thinking about sequencing therapies for these patients (IO vs chemo vs T-Dxd)? Are the data from DESTINY-Lung01 strong enough to warrant e...

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?  Do you feel the dosing used in...

Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...

Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan? Can data from ASCENT be applied to patients with C...

To what degree do you factor in patient preference when choosing among available treatments? Are there features of each regimen that you emphasize in ...

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?

What was the magnitude of benefit for patients with EGFRm NSCLC by stage?  Are you still considering adjuvant osimertinib for patients with earl...

Is data available regarding the percentages of patients in each arm who underwent staging PET or the breakdown of CNS imaging modalities?

If patients do recur, do you perform these tests on the initial surgical specimen or on tissue from a fresh biopsy (or both?)

Are the rates of adjuvant chemotherapy used in ADAURA consistent with real-world practice?

What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?

In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?


Papers discussed in this category


The New England journal of medicine, 2012-01-12

The New England journal of medicine, 2012-11-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

N Engl J Med,

N Engl J Med, 2019 Dec 11

Lancet Oncol., 2015-09-01

N Engl J Med, 2006 Jul 6

The New England journal of medicine, 2002-10-17

Ann. Surg., 2007-11-01

N Engl J Med, 2021-04-01

J Clin Oncol, 2021 Apr 23

Lancet,

BMC Cancer, 2016 Jul 19

J Hepatol, 2021 Nov 19

N Engl J Med, 2020 May 14

J Hepatol, 2021 Dec 11

N Engl J Med, 2021 Sep 18

The New England journal of medicine, 2018-05-31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

N Engl J Med, 2020 Sep 19

J Clin Oncol, 2020 Dec 04

Cancer Treat Rev, 2022 Mar 12

Liver Cancer, 2019 Sep 18

British journal of cancer, 2011-06-07

Lancet, 1998 Jul 25

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01

N. Engl. J. Med., 2019 Dec 11

J Clin Oncol, 2020 May 29

J Clin Oncol, 2011 Jun 1

Lancet Oncol., 2014 Dec 11

N Engl J Med,

Lancet Oncol, 2021 Mar 12

N Engl J Med, 2021 Feb 18

N Engl J Med, 2021 Jun 03

Ann Surg Oncol, 2019 Jul 24

J Clin Oncol, 2020 Mar 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-20

J Clin Oncol, 2015 Nov 1

N. Engl. J. Med.,

N. Engl. J. Med., 2017 Jun 04

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01

BMC Cancer, 2018 Mar 07

N Engl J Med,

JCO Oncol Pract, 2022 Jan 07

The New England journal of medicine, 2018-08-23

N. Engl. J. Med.,

Lancet Oncol, 2020 Aug 06

The Lancet. Oncology, 2018-04

JAMA Oncol,

European urology, 2014-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-02-01

Lancet, 2020 Mar 05

Nature, 2021 Jun 16

N Engl J Med, 2021 Apr 22

Cancer Discov, 2021 Aug 17

Ann Oncol, 2021 Mar 16

Annals of oncology : official journal of the European Society for Medical Oncology, 2001-09

Cochrane Database Syst Rev, 2021 May 26

The Lancet. Oncology, 2017-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10

JAMA Oncol,

Annals of surgery, 2009-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-10

The New England journal of medicine, 2018-07-12

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

J Thorac Oncol, 2020 Jan 13

J Immunother Cancer, 2019 Jan 21

ESMO Open, 2021 Aug 31

J Clin Oncol, 2021 Aug 03

Ann Rheum Dis, 2016 Oct 03

N Engl J Med,

Arthritis Rheumatol, 2021 Mar 24

The Lancet. Oncology, 2019-06

J Clin Oncol, 2020 Feb 14

N Engl J Med, 2021 Oct 28

The New England journal of medicine, 2018-07-19

N Engl J Med, 2013 Jun 26

N Engl J Med,

J. Clin. Oncol., 2018 May 30

N Engl J Med, 2022 Jun 05

N Engl J Med,

Int J Mol Sci, 2020 Sep 03